ArticleJournal of molecular histology2026
Platelet-rich plasma-primed bone marrow mesenchymal stem cell-derived exosomes inhibit neuronal apoptosis and autophagy, and promote nerve regeneration via the miR-29a-3p/PTEN/PI3K/Akt/mTOR axis after spinal cord injury.
Article in Journal of molecular histology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Both platelet-rich plasma (PRP) and exosomes derived from bone marrow mesenchymal stem cells (BMSCs) exhibit therapeutic potential for spinal cord injury (SCI). However, the combined application of PRP and BMSCs-derived exosome (PRP-primed BMSCs-EXO, PRP-BMSCs-EXO) has not been reported. This study aimed to investigate whether the combined use confers superior therapeutic effects and to explore the underlying molecular mechanisms. First, we examined the effects of PRP priming on the proliferation and exosome secretion of BMSCs. High-throughput sequencing and RT-qPCR were used to analyze the differential miRNA expression profiles between exosomes from PRP- primed BMSCs (PRP-BMSCs-EXO) and naive BMSCs (BMSCs-EXO). Subsequently, a series of in vitro SCI models were established to evaluate the therapeutic effects of PRP-BMSCs-EXO on SCI. TargetScan, RNAhybrid, GO, KEGG, dual-luciferase reporter assay, RT-qPCR, western blotting (WB), and rescue experiments were performed to explore the roles of miRNAs in PRP-BMSCs-EXO and the associated signaling regulatory mechanisms in SCI. Finally, a series of in vivo SCI models were used to verify the therapeutic efficacy and mechanisms of PRP-BMSCs-EXO in vivo. PRP priming promoted the proliferation and exosome secretion of BMSCs. High-throughput sequencing and RT-qPCR revealed that multiple miRNAs were highly expressed in PRP-BMSCs-EXO compared with BMSCs-EXO, among which miR-29a-3p was the most abundant. In in vitro SCI models, PRP-BMSCs-EXO exerted better therapeutic effects than BMSCs-EXO and PRP. Mechanistically, PRP-BMSCs-EXO may enhance the viability and migration and inhibit the apoptosis and autophagy of pheochromocytoma 12 (PC12) cells by delivering miR-29a-3p, thereby promoting nerve regeneration and SCI repair. Bioinformatic analysis and luciferase assays indicated that PTEN may be a downstream target gene of miR-29a-3p. Rescue experiments confirmed that the miR-29a-3p/PTEN/PI3K/Akt/mTOR axis may mediate the regulatory effects of PRP-BMSCs-EXO on neuronal apoptosis, autophagy, and nerve regeneration in SCI. These findings were further validated in in vivo SCI models. Compared with PRP and BMSC-derived exosomes alone, PRP-primed BMSC-derived exosomes provide superior neuroprotective effects against SCI. PRP-BMSCs-EXO inhibits neuronal apoptosis and autophagy and promotes nerve regeneration via the miR-29a-3p/PTEN/PI3K/Akt/mTOR axis, representing a promising and effective therapeutic strategy for SCI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.